Trombotic microangiopathy – a nephrologists‘ view
Jan Vachek Orcid.org 1, Oskar Zakiyanov1, Vít Motáň2, Vladimír Tesař Orcid.org 1
+ Affiliation
Summary
Thrombotic microangiopathy (TMA) is a syndrome characterised by haemolytic anaemia with fragmented red blood cells (schistocytes) in peripheral blood, thrombocytopenia caused by increased platelet aggregation and consumption, resulting in a disturbance of microcirculation caused by a formation of microthrombi. Vascular occlusion causes tissue and organ ischaemia that results in functional disorders of various organs, mainly the central nervous system, kidneys, heart, lungs and gut. Idiopathic TMAs include two etiologically distinct categories known as thrombotic thrombocytopenic purpura and haemolytic uremic syndrome. Secondary TMAs may be caused by certain drugs, infections, malignancies, systemic diseases, or associated with pregnancy. TMA is a rare disease; the reported incidence rates of idiopathic TMA range from one to four patients per million persons year. However, due to the heterogeneity of clinical symptoms, any physician can come across patients suffering from TMA. Timely diagnosis and appropriate treatment are crucial for the outcome of the patients, otherwise the affected patients are threatened with rapid progressive decline of vital functions. This article aims to provide a brief overview of thrombotic microangiopathies and highlights certain novel diagnostic and therapeutic approaches. In addition, the article helps increase general awareness of these diseases, specifically in view of possible difficulties in diagnosis and classification of clinical categories of TMAs.
Keywords
eculizumab, hemolytická anemie, haemolytic uremic syndrome, thrombocytopenia, thrombotic thrombocytopenic purpura, plasma exchangeLiterature
1. Nangaku M, Nishi H, Fujita T. Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol 2007; 11 (2): 107–114.
2. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Ann Rev Med 2006; 57: 419–436.
3. Adler M, Kremer Hovinga JA, Lämmle B. Thrombotic thrombocytopenic purpuran – an often missed diagnosis. Rev Med Suisse 2014; 10 (452): 2280–2284.
4. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic‑uremic syndrome. N Engl J Med 2013; 368 (23): 2169–2181. doi: 10.1056/NEJMoa1208981.
5. Bennett CL, Weinberg PD, Rozenberg‑Ben‑Dror K et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128 (7): 541–544.
6. Knoebl P. Blood coagulation disorders in septic patients. Wien Med Wochenschr 2010; 160 (5–6): 129–138. doi: 10.1007/s103 54‑009‑0738‑9.
7. Merayo‑Chalico J, Demichelis‑Gómez R, Rajme‑López S et al. Risk factors and clinical profile of thrombotic thrombo- cytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: a case con- trol study. Thromb Res 2014; 134 (5): 1020–1027. doi: 10.1016/j.thromres.2014. 09.005.
8. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today’s understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010; 169 (1): 7–13. doi: 10.1007/ s00431‑009‑1039‑4.
9. Khandelwal P, Gupta A, Sinha A et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti‑complement factor H antibody‑associated hemolytic uremic syndrome. Pediatr Nephrol 2015; 30 (3): 451–457. doi: 10.1007/s00467‑014‑2948‑7.
10. Delmas Y, Vendrely B, Clouzeau B et al. Outbreak of Escherichia coli O104: H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29 (3): 565–572. doi: 10.1093/ndt/gft470.
11. Cullinan N, Gorman KM, Riordan M et al. Case report: Benefits and challenges of long‑term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015; 135 (6): e1506–e1509. doi: 10.1542/peds.2014‑3503.